Sage Therapeutics (NASDAQ:SAGE) had its target price hoisted by investment analysts at Leerink Swann from $123.00 to $246.00 in a report issued on Thursday. Leerink Swann’s target price would indicate a potential upside of 167.68% from the stock’s current price.

A number of other equities analysts have also recently weighed in on SAGE. BMO Capital Markets reissued an “outperform” rating and issued a $203.00 price target on shares of Sage Therapeutics in a research note on Thursday. Royal Bank Of Canada raised their price objective on Sage Therapeutics from $137.00 to $280.00 and gave the stock a “sell” rating in a research report on Thursday. They noted that the move was a valuation call. Stifel Nicolaus initiated coverage on Sage Therapeutics in a research report on Wednesday, August 9th. They set a “buy” rating and a $104.00 price objective for the company. BidaskClub lowered Sage Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, August 23rd. Finally, Chardan Capital restated a “hold” rating on shares of Sage Therapeutics in a research report on Wednesday, September 13th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $130.64.

Shares of Sage Therapeutics (NASDAQ SAGE) traded up $2.11 on Thursday, reaching $91.90. The company had a trading volume of 570,600 shares, compared to its average volume of 548,792. Sage Therapeutics has a 1 year low of $44.55 and a 1 year high of $100.50.

Sage Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.97) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.98) by $0.01. Sage Therapeutics’s revenue was up .0% on a year-over-year basis. analysts expect that Sage Therapeutics will post -7.4 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in SAGE. BlackRock Inc. lifted its holdings in shares of Sage Therapeutics by 5.9% during the 2nd quarter. BlackRock Inc. now owns 3,031,548 shares of the biopharmaceutical company’s stock valued at $241,431,000 after buying an additional 168,424 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Sage Therapeutics by 2.2% during the 2nd quarter. Vanguard Group Inc. now owns 2,749,954 shares of the biopharmaceutical company’s stock valued at $219,006,000 after buying an additional 58,679 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Sage Therapeutics by 36.5% during the 3rd quarter. Bank of New York Mellon Corp now owns 2,710,027 shares of the biopharmaceutical company’s stock valued at $168,834,000 after buying an additional 724,494 shares during the last quarter. State Street Corp lifted its holdings in shares of Sage Therapeutics by 7.7% during the 2nd quarter. State Street Corp now owns 1,212,384 shares of the biopharmaceutical company’s stock valued at $96,558,000 after buying an additional 87,097 shares during the last quarter. Finally, Oak Ridge Investments LLC lifted its holdings in shares of Sage Therapeutics by 0.9% during the 3rd quarter. Oak Ridge Investments LLC now owns 736,709 shares of the biopharmaceutical company’s stock valued at $45,897,000 after buying an additional 6,835 shares during the last quarter. Hedge funds and other institutional investors own 95.40% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://www.americanbankingnews.com/2017/12/07/sage-therapeutics-sage-price-target-increased-to-246-00-by-analysts-at-leerink-swann.html.

About Sage Therapeutics

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Analyst Recommendations for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.